Global Development Lead (GDL), Clinical Development

Role: Serve as Global Development Lead (GDL) for a late-stage oncology program specializing in RAS-mutant cancers, with end-to-end ownership of clinical strategy and execution. Responsibilities include defining and integrating clinical development plans, overseeing pivotal Phase 2/3 trials, managing regulatory interactions, and providing scientific leadership in pancreatic and colorectal cancers. The GDL acts as the primary clinical authority, guiding cross-functional teams, engaging key opinion leaders, and representing the program externally. Qualifications: MD with board certification in Medical Oncology or Hematology, at least 13 years of oncology clinical development experience, including global late-stage trial leadership, regulatory strategy, and submissions. High-value biopharma specifics encompass targeted RAS inhibitors in various mutation-specific modalities (G12C, G12D, G12V), with a focus on late-stage (Phase 2/3) clinical development, regulatory engagement, and strategic planning. The role involves leading a multidisciplinary team, influencing senior stakeholders, and contributing to enterprise-level development discussions. Preferred skills include academic leadership, translational research integration, publication record, and experience in commercialization planning. Location: hybrid or onsite in Redwood City, CA, with 25-30% travel.